Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 1/20 | 0.60 |
| ▸ | NT5E | P21589 | 15/20 | 0.56 |
| ▸ | PDE2A | O00408 | 2/20 | 0.54 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1895610 | 1.00 | TYMP (0.60) | TYMPNT5EPDE2AADORA1 | |
| SCHEMBL12642132 | 0.95 | TYMP (0.57) | TYMPNT5EPDE2AADORA1 | |
| SCHEMBL7895839 | 0.94 | TYMP (0.69) | TYMPNT5EADORA1 | |
| SCHEMBL7615059 | 0.92 | TYMP (0.59) | TYMPNT5EADORA1 | |
| SCHEMBL7615063 | 0.92 | TYMP (0.59) | TYMPNT5EADORA1 | |
| SCHEMBL19949285 | 0.92 | NT5E (0.67) | NT5EPDE2A | |
| SCHEMBL30262593 | 0.92 | NT5E (0.67) | NT5EPDE2A | |
| SCHEMBL29799117 | 0.89 | NT5E (0.65) | TYMPNT5EADORA1 | |
| SCHEMBL7615396 | 0.89 | TYMP (0.57) | TYMPNT5EADORA1 | |
| SCHEMBL7615405 | 0.89 | TYMP (0.57) | TYMPNT5EADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110257244-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES AND SMALL MOLECULES FOR USE IN REDUCING MICRO RNA ACTIVITY LEVELS AND USES THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110130440-A1 | NON-NATURAL RIBONUCLEOTIDES, AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-06-02 | — | — | US | disclosed |
| US-20110118339-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES AND USES THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-05-19 | — | — | US | disclosed |
| US-20110065774-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES AND USES THEREOF | ALNYLAM PHARMACEUTICALS (US) | 2011-03-17 | — | — | US | disclosed |
| WO-2009120878-A2 | NON-NATURAL RIBONUCLEOTIDES, AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-10-01 | — | — | WO | disclosed |
| WO-2009091982-A1 | MIR-122 AGONIST | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-07-23 | — | — | WO | disclosed |
| WO-2009091972-A2 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES AND SMALL MOLECULES FOR USE IN REDUCING MICRO RNA ACTIVITY LEVELS AND USES THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257244-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES AND SMALL MOLECULES FOR USE IN REDUCING MICRO RNA ACTIVITY LEVELS AND USES THEREOF | AGO2, BCDIN3D, TRDMT1 | TYMP 1431/4885NT5E 344/4885PDE2A 2864/4885 |
| US-20110065774-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES AND USES THEREOF | DCLRE1B, RNGTT, NSUN2 | TYMP 88/4885NT5E 32/4885PDE2A 4258/4885 |
| US-20110130440-A1 | NON-NATURAL RIBONUCLEOTIDES, AND METHODS OF USE THEREOF | NSUN2, RNMT, RNGTT | TYMP 237/4885NT5E 40/4885PDE2A 3058/4885 |
| US-20110118339-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES AND USES THEREOF | TRDMT1, NSUN3, BCDIN3D | TYMP 326/4885NT5E 38/4885PDE2A 4029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.